Skip to main content
lexblog.com/lib/TPVQJN66viewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "CMA Fines GlaxoSmithKline and Several Generic Companies £45 million for Delaying Market Entry of Generic Paroxetine in the UK",
    "url": "https://www.lexblog.com/2016/02/12/cma-fines-glaxosmithkline-and-several-generic-companies-45-million-for-delaying-market-entry-of-generic-paroxetine-in-the-uk-2/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-TPVQJN66",
        "url": "https://www.lexblog.com/lib/TPVQJN66/"
    },
    "datePublished": "2016-02-12T13:23:47-05:00",
    "dateModified": "2022-08-25T14:22:24-04:00",
    "author": {
        "@type": "Person",
        "name": "Inside EU Life Sciences"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Covington & Burling LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Inside EU Life Sciences",
    "about": "Antitrust, Competition and Trade",
    "sourceUrl": "https://www.insideeulifesciences.com/?p=6481",
    "sourceStability": "may-move"
}